Rallybio Corporaton (RLYB)

Jan 10, 2025, 8:00 AM EST - 7 days ago

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

Dec 10, 2024, 8:00 AM EST - 5 weeks ago

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Dec 2, 2024, 8:00 AM EST - 6 weeks ago

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Nov 27, 2024, 8:00 AM EST - 7 weeks ago

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Nov 26, 2024, 8:00 AM EST - 7 weeks ago

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Nov 25, 2024, 8:00 AM EST - 7 weeks ago

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Nov 21, 2024, 8:00 AM EST - 2 months ago

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Nov 7, 2024, 8:00 AM EST - 2 months ago

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Oct 29, 2024, 8:00 AM EDT - 2 months ago

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Sep 30, 2024, 8:00 AM EDT - 3 months ago

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Sep 23, 2024, 8:00 AM EDT - 4 months ago

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

Sep 10, 2024, 8:00 AM EDT - 4 months ago

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Sep 9, 2024, 5:15 PM EDT - 4 months ago

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

Aug 29, 2024, 8:00 AM EDT - 5 months ago

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis

Aug 27, 2024, 8:00 AM EDT - 5 months ago

National Vision Releases 2023 Sustainability Report

ACNT

Aug 27, 2024, 8:00 AM EDT - 5 months ago

Rallybio to Present at Upcoming Investor Conferences

Aug 8, 2024, 8:00 AM EDT - 5 months ago

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 9, 2024, 8:00 AM EDT - 6 months ago

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

Jun 17, 2024, 8:00 AM EDT - 7 months ago

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

May 9, 2024, 8:00 AM EDT - 9 months ago

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

May 7, 2024, 8:00 AM EDT - 9 months ago

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

Apr 17, 2024, 4:01 PM EDT - 9 months ago

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

Apr 10, 2024, 4:01 PM EDT - 10 months ago

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Apr 1, 2024, 10:05 AM EDT - 10 months ago

Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting

Mar 12, 2024, 8:00 AM EDT - 11 months ago

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 8:00 AM EST - 11 months ago

Rallybio to Present at the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Portfolio Prioritization and Provides Corporate Update

Jan 4, 2024, 8:00 AM EST - 1 year ago

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

Dec 20, 2023, 8:00 AM EST - 1 year ago

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Dec 9, 2023, 12:00 PM EST - 1 year ago

Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting

Nov 28, 2023, 7:00 AM EST - 1 year ago

Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Nov 9, 2023, 8:00 AM EST - 1 year ago

Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 8, 2023, 8:00 AM EST - 1 year ago

Rallybio to Present at Upcoming Investor Conferences in November

Nov 2, 2023, 9:15 AM EDT - 1 year ago

Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Oct 3, 2023, 8:00 AM EDT - 1 year ago

Rallybio to Present at the JonesTrading 2023 Healthcare Summit

Sep 15, 2023, 5:15 PM EDT - 1 year ago

Rallybio: Gearing Up To Be An Opportunity

Sep 3, 2023, 12:00 PM EDT - 1 year ago

Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Aug 31, 2023, 8:00 AM EDT - 1 year ago

Rallybio to Present at Upcoming Investor Conferences in September

Aug 8, 2023, 8:00 AM EDT - 1 year ago

Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates

Aug 2, 2023, 8:00 AM EDT - 1 year ago

Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference

Jul 11, 2023, 8:00 AM EDT - 1 year ago

Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)

Jun 29, 2023, 7:00 AM EDT - 1 year ago

Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023

Jun 24, 2023, 3:30 PM EDT - 1 year ago

Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

Jun 9, 2023, 9:15 AM EDT - 1 year ago

Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis

Jun 1, 2023, 8:00 AM EDT - 1 year ago

Rallybio to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 1 year ago

Rallybio Reports First Quarter 2023 Financial Results

May 8, 2023, 8:00 AM EDT - 1 year ago

Rallybio to Present at the JMP Securities 2023 Life Sciences Conference

Apr 6, 2023, 8:00 AM EDT - 1 year ago

Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis

Apr 3, 2023, 8:00 AM EDT - 1 year ago

Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)

Mar 6, 2023, 8:00 AM EST - 2 years ago

Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results